Journal Article (Review Article)

DKFZ-2024-00190

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Alpha-Emitting Radionuclides: Current Status and Future Perspectives.

Miederer, M. ; Benešová-Schäfer, M.DKFZ* ; Mamat, C. ; Kästner, D. ; Pretze, M. ; Michler, E. ; Brogsitter, C. ; Kotzerke, J. ; Kopka, K.DKFZ* ; Scheinberg, D. A. ; McDevitt, M. R.

2024
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/ph17010076

Abstract: The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.

Keyword(s): actinium-225 ; alpha emitter ; high let ; targeted alpha therapy ; theranostic

---

Contributing Institute(s):

1. NWG Molekularbiologie Systemischer Radiotherapie (E270)
2. DKTK Koordinierungsstelle Dresden (DD01)

Research Program(s):

1. 315 - Bildgebung und Radioonkologie (POF4-315) (POF4-315)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---